血管抑素对糖尿病大鼠视网膜组织变化及其VEGF的差异表达被引量：2

Retinal Tissue Changes and the Expression of VEGF after Angiostatin Inhibition in Diabetic Rats

导出

摘要目的研究血管抑素体内抑制视网膜新生血管形成疗效及对血管内皮细胞生长因子(vascular endothelial growth factor,VEGF)表达的影响。方法建立链脲佐菌素糖尿病大鼠模型,分A组(造模实验组),B组(造模对照组),每组36只,取正常SD大鼠36只作为C组(正常对照组)。予以玻璃体腔内注射血管抑素后观察视网膜HE染色结果及大鼠的视网膜VEGF的表达。结果 A、B组大鼠的血糖值明显高于同期C组;A组即注射血管抑素与B组即注射磷酸盐缓冲液(phosphate buffer solution,PBS)相比,视网膜的细胞排列有一定规则,组织水肿不明显;A组视网膜的VEGF水平明显低于B组,且都高于C组。结论血管抑素可明显降低糖尿病鼠视网膜组织的VEGF表达,能有效抑制糖尿病大鼠视网膜组织水肿及内部组织结构的改变。因此,血管抑素有潜在预防和治疗糖尿病性视网膜病变的价值。 Objective To investigate the inhibitory effect of Angiostatin on retinal neovascularization in vivo and the expression of vascular endothelial growth factor（VEGF）.Methods One hundred and eight male adult Sprague-Dawley rats were induced for diabetes by an intraperitoneal injection of streptozotocin,then randomly divided into the model group（A）and normal group（B）.And 36 SD rats as the normal control group（C）.After intravitreal injection of vascular inhibition in rats,the retinal results were observed by HE staining and the expression of VEGF were evaluated by Western blotting.Results In the same time,the blood glucose of group A and group B were significantly higher than group C.Comparing the vascular inhibition injection in group A with PBS injectione in group B,there were regular arrangement and obscured edema of retinal cell tissue.VEGF level of retinal in group A was significantly lower than group B,both groups had higher level of VEGF than group C.Conclusions Angiostatin can obviously reduce VEGF expression,tissue edema and internal structural changes of retinal in diabetic rat.Consequently,angiostatin is potential to be used in prevention and treatment of diabetic retinopathy.

作者丰玲玲付茜刘海俊王芳余惠芳翁永德

机构地区解放军海军

出处《华南国防医学杂志》 CAS 2014年第12期1167-1170,共4页 Military Medical Journal of South China

基金广东省科技计划项目(2011B31800266)

关键词血管抑素 VEGF 糖尿病视网膜 Angiostatin Vascular endothelial growth factor Diabetes Retina

分类号 R392 [医药卫生—免疫学]

引文网络
相关文献

参考文献11

1熊朝晖,孙朝晖,冯艳霞,李亚楠,王会芳,王海燕,王桂琦.依帕司他治疗早期糖尿病性白内障的临床评价[J].华南国防医学杂志,2014,28(8):826-827. 被引量：2
2Robison WG, Lawer NM, Jacot JL. Efficacy of treatment after measurable diabetic like retiopathy in galactese fedrats [J].Invest Ophthalmol Vis Sei, 1997,38 (6) :1066-1072.
3Carter JG, Cherry J, Williams K, et al. Splicing factor polymor- phisms, the control of VEGF isoforms and association with an- giogenic eye disease[J].Curr Eye Res, 2011, 36 (4) : 328-335.
4Vailati FB, Crispim D, Sortica DA, et al.The C allele of -634G/C polymorphism in the VEGFA gene is associated with increased VEGFA gene expression in human retinal tissue[J]. Invest Opthalmol Vis Sci, 2012,53 (10) : 6411-6415.
5Arevalo JF, Wu L, Sanchez JG, et al. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months fol- low-up[J].Eye, 2007,23(1) : 117-123.
6Hasanreisoglu M, Weinberger D, Mimouni K, et al. Intravitreal bevaeizumab as adjunct for neovacular glaueoma[J].Eur J Oph thalmol,2009,19(4) :607-612.
7Mohan N, Monickaraj F, Balasubramanyam M, et al. Imbalanced levels of angiogenic and angiostatic factors in vitreous, plasma and postmortem retinal tissue of patients with proliferative dia- betic retinopathy[J].J Diabetes Complication, 2012,26 (5) : 435- 441.
8叶湘湘,陈中山,丁琴,宋艳萍.VEGF基因RNA干扰质粒的构建与鉴定[J].华南国防医学杂志,2013,27(5):299-304. 被引量：3
9Wu H, Jiang J, Wu J, et al. High glucose attenuates insulin-in duced VEGF expression in bovine retinal microvreaseular endo- thelial cells[J].Eye,2010,24(1 ) : 145- 151.
10Hutchings H, Maitre-Boube M, Tombran-Tink J,et al.Pigment epithelium-derived factor exerts opposite effects on endothelial cells of different phenotypes[J].Biochem Biophys Res Commun, 2002,294(4) : 764-769.

二级参考文献44

1潘映福.临床诱发电位学[M].北京：人民卫生出版社,1988.245-72.
2Churchill AJ, Carter JG, Lovell HC, et al. VEGF polymorphisms are associated with neovascular age-related maeular degeneration [J]. Hum Mol Genet,2006,15(19) :2955-2961.
3Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration[J]. N Engl J Meal,2006,355(14) .. 1432-1444.
4Rosenfeld PJ,Brown DM, Heier JS, et al. Ranibizumab for neo- vascular age-related macular degeneration [J]. N Engl J Med, 2006,355(14) : 1419-1431.
5Ashikari M, Tokoro M, Itaya M, et al. Suppression of laser-in- duced ehoroidal neovascuIarization by nontargeted siRNA[J]. In- vest Ophthalmol Vis Sei, 2010,51 (7) : 3820-3824.
6Rajappa M, Saxena P, Kaur J. Ocular angiogenesis mechanisms and recent advances in therapy[J]. Adv Clin Chem, 2010,50.. 103- 121.
7Bhisitkul RB. Vascular endothelial growth factor biology: clinical implications for ocular treatments[J]. Br J Ophthalmol, 2006, 90 (12) 1542-1547.
8Cunningham El" Jr, Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular en- dothelial growth factor aptamer, for diabetic macular edema[J]. Ophthalmology, 2005,112(10) : 1747-1757.
9Golf MJ, Johnson RN, McDonald HR, et al. Intravitreal bevaci- zumab for previously treated choroidal neovaseularization from age-related maeular degeneration[J]. Retina, 2007,27 (4) 432-438.
10Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treat- ment of neovascular age-related macular degeneration..a phase I/II multicenter, controlled, multidose study [J]. Ophthalmology, 2006,113 (4) : 633, el-e4.